Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Fluorouracil + IGM-8444 + Irinotecan + Leucovorin |
Synonyms | FOLFIRI + IGM-8444 |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Fluorouracil | Adrucil | 5-FU|5-Fluorouracil | Chemotherapy - Antimetabolite 14 | Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent, which interferes with DNA and RNA synthesis thereby preventing cancer cell growth and is FDA approved for colorectal, breast, stomach, and pancreatic cancer (FDA.gov). |
IGM-8444 | IGM8444|IGM 8444 | IGM-8444 is a multivalent agonistic antibody that targets and activates Death Receptor 5 (TNFRSF10B), potentially resulting in increased cytotoxicity and apoptosis, and inhibition of tumor growth (Journal of Clinical Oncology 2020 38:15_suppl, 3595; Cancer Res 2020;80(16 Suppl):Abstract nr 518). | ||
Irinotecan | Camptosar | CPT-11 | TOPO1 inhibitor 11 | Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov). |
Leucovorin | Wellcovorin | Calcium folinate|Calcium citrovorum factor|folinic acid | Chemotherapy - Antimetabolite 14 | Wellcovorin (leucovorin) is a metabolite of folate that enhances the efficacy of fluoruracil (PMID: 32490554). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04553692 | Phase I | Bevacizumab + Fluorouracil + IGM-8444 + Irinotecan + Leucovorin Fluorouracil + IGM-8444 + Irinotecan + Leucovorin IGM-8444 | Study of IGM-8444 as a Single Agent and in Combination With Chemotherapy-based Regimens in Subjects With Solid Cancers | Active, not recruiting | USA | FRA | ESP | AUS | 1 |